Logo image of AUPH

AURINIA PHARMACEUTICALS INC (AUPH) Stock Fundamental Analysis

NASDAQ:AUPH - Nasdaq - CA05156V1022 - Common Stock - Currency: USD

8.18  -0.05 (-0.61%)

After market: 8.1637 -0.02 (-0.2%)

Fundamental Rating

6

AUPH gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 559 industry peers in the Biotechnology industry. AUPH is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. AUPH is growing strongly while it also seems undervalued. This is an interesting combination These ratings would make AUPH suitable for value and growth investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

AUPH had positive earnings in the past year.
AUPH had a positive operating cash flow in the past year.
AUPH had negative earnings in 4 of the past 5 years.
AUPH had negative operating cash flow in 4 of the past 5 years.
AUPH Yearly Net Income VS EBIT VS OCF VS FCFAUPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

AUPH has a Return On Assets of 7.89%. This is amongst the best in the industry. AUPH outperforms 94.10% of its industry peers.
AUPH's Return On Equity of 11.38% is amongst the best of the industry. AUPH outperforms 94.28% of its industry peers.
AUPH has a better Return On Invested Capital (8.56%) than 94.45% of its industry peers.
Industry RankSector Rank
ROA 7.89%
ROE 11.38%
ROIC 8.56%
ROA(3y)-12.06%
ROA(5y)-18.32%
ROE(3y)-15.27%
ROE(5y)-21.75%
ROIC(3y)N/A
ROIC(5y)N/A
AUPH Yearly ROA, ROE, ROICAUPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

Looking at the Profit Margin, with a value of 16.11%, AUPH belongs to the top of the industry, outperforming 94.28% of the companies in the same industry.
Looking at the Operating Margin, with a value of 19.56%, AUPH belongs to the top of the industry, outperforming 95.35% of the companies in the same industry.
AUPH's Gross Margin of 88.24% is amongst the best of the industry. AUPH outperforms 90.88% of its industry peers.
AUPH's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 19.56%
PM (TTM) 16.11%
GM 88.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.39%
GM growth 5YN/A
AUPH Yearly Profit, Operating, Gross MarginsAUPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so AUPH is destroying value.
The number of shares outstanding for AUPH has been reduced compared to 1 year ago.
Compared to 5 years ago, AUPH has more shares outstanding
AUPH has a better debt/assets ratio than last year.
AUPH Yearly Shares OutstandingAUPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
AUPH Yearly Total Debt VS Total AssetsAUPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 3.36 indicates that AUPH is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.36, AUPH is in the better half of the industry, outperforming 75.13% of the companies in the same industry.
The Debt to FCF ratio of AUPH is 1.11, which is an excellent value as it means it would take AUPH, only 1.11 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 1.11, AUPH belongs to the best of the industry, outperforming 94.81% of the companies in the same industry.
A Debt/Equity ratio of 0.16 indicates that AUPH is not too dependend on debt financing.
AUPH has a worse Debt to Equity ratio (0.16) than 68.69% of its industry peers.
Even though the debt/equity ratio score it not favorable for AUPH, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF 1.11
Altman-Z 3.36
ROIC/WACC0.61
WACC13.96%
AUPH Yearly LT Debt VS Equity VS FCFAUPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

AUPH has a Current Ratio of 5.93. This indicates that AUPH is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 5.93, AUPH is doing good in the industry, outperforming 60.82% of the companies in the same industry.
AUPH has a Quick Ratio of 5.26. This indicates that AUPH is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of AUPH (5.26) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.93
Quick Ratio 5.26
AUPH Yearly Current Assets VS Current LiabilitesAUPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

7

3. Growth

3.1 Past

AUPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 171.79%, which is quite impressive.
AUPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 29.20%.
AUPH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 279.17% yearly.
EPS 1Y (TTM)171.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%633.33%
Revenue 1Y (TTM)29.2%
Revenue growth 3Y72.76%
Revenue growth 5Y279.17%
Sales Q2Q%24.18%

3.2 Future

Based on estimates for the next years, AUPH will show a very strong growth in Earnings Per Share. The EPS will grow by 71.70% on average per year.
AUPH is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.03% yearly.
EPS Next Y580%
EPS Next 2Y196.94%
EPS Next 3Y131.64%
EPS Next 5Y71.7%
Revenue Next Year9.69%
Revenue Next 2Y13.92%
Revenue Next 3Y14.89%
Revenue Next 5Y12.03%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
AUPH Yearly Revenue VS EstimatesAUPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
AUPH Yearly EPS VS EstimatesAUPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 0.5 -0.5 1 -1

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

AUPH is valuated quite expensively with a Price/Earnings ratio of 29.21.
AUPH's Price/Earnings ratio is rather cheap when compared to the industry. AUPH is cheaper than 94.10% of the companies in the same industry.
When comparing the Price/Earnings ratio of AUPH to the average of the S&P500 Index (26.31), we can say AUPH is valued inline with the index average.
A Price/Forward Earnings ratio of 10.31 indicates a reasonable valuation of AUPH.
AUPH's Price/Forward Earnings ratio is rather cheap when compared to the industry. AUPH is cheaper than 96.06% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.13, AUPH is valued rather cheaply.
Industry RankSector Rank
PE 29.21
Fwd PE 10.31
AUPH Price Earnings VS Forward Price EarningsAUPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

97.14% of the companies in the same industry are more expensive than AUPH, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, AUPH is valued cheaply inside the industry as 94.81% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 17.27
EV/EBITDA 9.1
AUPH Per share dataAUPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

AUPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as AUPH's earnings are expected to grow with 131.64% in the coming years.
PEG (NY)0.05
PEG (5Y)N/A
EPS Next 2Y196.94%
EPS Next 3Y131.64%

More info and screens

0

5. Dividend

5.1 Amount

AUPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AURINIA PHARMACEUTICALS INC

NASDAQ:AUPH (6/13/2025, 8:00:01 PM)

After market: 8.1637 -0.02 (-0.2%)

8.18

-0.05 (-0.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/bmo
Earnings (Next)07-30 2025-07-30
Inst Owners46.86%
Inst Owner Change7.99%
Ins Owners2.23%
Ins Owner Change8.63%
Market Cap1.11B
Analysts81.67
Price Target10.34 (26.41%)
Short Float %8.96%
Short Ratio8.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)109.07%
Min EPS beat(2)56.86%
Max EPS beat(2)161.28%
EPS beat(4)4
Avg EPS beat(4)197.36%
Min EPS beat(4)17.69%
Max EPS beat(4)553.6%
EPS beat(8)7
Avg EPS beat(8)119.79%
EPS beat(12)10
Avg EPS beat(12)89.11%
EPS beat(16)13
Avg EPS beat(16)66.53%
Revenue beat(2)0
Avg Revenue beat(2)-1.28%
Min Revenue beat(2)-2.09%
Max Revenue beat(2)-0.48%
Revenue beat(4)2
Avg Revenue beat(4)3.61%
Min Revenue beat(4)-2.09%
Max Revenue beat(4)15.16%
Revenue beat(8)5
Avg Revenue beat(8)7.94%
Revenue beat(12)9
Avg Revenue beat(12)11.49%
Revenue beat(16)13
Avg Revenue beat(16)11.96%
PT rev (1m)1.67%
PT rev (3m)1.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)35.19%
EPS NY rev (1m)0%
EPS NY rev (3m)4.9%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.45%
Valuation
Industry RankSector Rank
PE 29.21
Fwd PE 10.31
P/S 4.47
P/FCF 17.27
P/OCF 17.19
P/B 3.16
P/tB 3.19
EV/EBITDA 9.1
EPS(TTM)0.28
EY3.42%
EPS(NY)0.79
Fwd EY9.7%
FCF(TTM)0.47
FCFY5.79%
OCF(TTM)0.48
OCFY5.82%
SpS1.83
BVpS2.59
TBVpS2.56
PEG (NY)0.05
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 7.89%
ROE 11.38%
ROCE 11.08%
ROIC 8.56%
ROICexc 30.16%
ROICexgc 31.21%
OM 19.56%
PM (TTM) 16.11%
GM 88.24%
FCFM 25.88%
ROA(3y)-12.06%
ROA(5y)-18.32%
ROE(3y)-15.27%
ROE(5y)-21.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.39%
GM growth 5YN/A
F-Score8
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF 1.11
Debt/EBITDA 0.84
Cap/Depr 1.47%
Cap/Sales 0.12%
Interest Coverage 250
Cash Conversion 94.79%
Profit Quality 160.62%
Current Ratio 5.93
Quick Ratio 5.26
Altman-Z 3.36
F-Score8
WACC13.96%
ROIC/WACC0.61
Cap/Depr(3y)6.1%
Cap/Depr(5y)121.69%
Cap/Sales(3y)0.25%
Cap/Sales(5y)3.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)171.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%633.33%
EPS Next Y580%
EPS Next 2Y196.94%
EPS Next 3Y131.64%
EPS Next 5Y71.7%
Revenue 1Y (TTM)29.2%
Revenue growth 3Y72.76%
Revenue growth 5Y279.17%
Sales Q2Q%24.18%
Revenue Next Year9.69%
Revenue Next 2Y13.92%
Revenue Next 3Y14.89%
Revenue Next 5Y12.03%
EBIT growth 1Y170.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year6475.33%
EBIT Next 3Y383.48%
EBIT Next 5YN/A
FCF growth 1Y198.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y199.75%
OCF growth 3YN/A
OCF growth 5YN/A